Title:Recent Patent-Based Perspective on Diagnostic and Therapeutic Interventions in Malignant Mesothelioma: Is Drug Repositioning Knocking on the Door?
Volume: 16
Issue: 2
Author(s): Vikas Yadav *Roghaiyeh Safari
Affiliation:
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Sart-Tilman, 4000, Liege,Belgium
Keywords:
Malignant mesothelioma, recent patent, clinical trials, epigenetics, immunotherapy, microRNA, virotherapy, drug
repositioning.
Abstract:
Background: Malignant Mesothelioma (MM), an orphan but aggressive malignancy of
the mesothelial membrane, is a fatal tumour. Global epidemic related to malignant pleural mesothelioma
is on the rise, so there is a need to explore novel biomarkers and ingenious therapeutic approaches
to stalk this silent killer.
Objective: The main aim of the present review is to provide a consolidated overview of the recent
active patents related to diagnosis and therapy in the field of MM that will impact its future management.
Methods: A search of existing literature was conducted from a PubMed database search. Recent patent
information was fetched out from online free open-access databases. For related clinical trials,
www.clinicaltrial.gov was searched.
Results: Patent search data showed 72 active patents related to diagnosis and therapy in the field of
MM, which we classified into eight broad categories. Of these, maximum 17 patents were attributed
to immunotherapy and 13 were attributed to “Drug Repositioning” and “Biological / synthetic”
based candidates. Relatively low number of patents accounts for gene signature (7), epigenetics (3)
and microRNA (2) based diagnosis and therapy. Remaining 17 patents were distributed amongst virotherapy
and various miscellaneous categories. Furthermore, our clinical trial based investigation
revealed the futuristic impact of listed patents in MM patient management.
Conclusion: This review article has provided an overview of patent based advancement in the field
of MM, which might become apex in the clinical settings in future. Interestingly, immunotherapy
and “drug repositioning” based therapy seems to be the front-runners in the race to provide relief.
